Physician profile
Timothy William West
NPI 1861650731
$856,461.02
in general payments reported to CMS, 2019-2025
42 companies · $95K in 2025
The $95K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219K · 2020: $137K · 2021: $101K · 2022: $102K · 2023: $127K · 2024: $75K · 2025: $95K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $247K · Travel and Lodging: $30K · Consulting Fee: $13K · Food and Beverage: $6,658 · Education: $38.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $247,370.32 |
| Travel and Lodging | $30,359.61 |
| Consulting Fee | $13,056.00 |
| Food and Beverage | $6,657.79 |
| Education | $38.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $402,629.19 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Emd Serono, INC. | $209,099.83 | 2019-2025 | Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $111,277.15 | 2022-2025 | Briumvi |
| Novartis Pharmaceuticals Corporation | $56,193.38 | 2019-2023 | |
| Genzyme Corporation | $42,019.26 | 2019-2024 | |
| Genentech USA, INC. | $17,320.81 | 2019-2024 | Ocrevus, Enspryng |
| Amgen INC. | $7,770.22 | 2024-2025 | Uplizna |
| Novartis Pharma Ag | $6,916.00 | 2021 | |
| Celgene Corporation | $1,188.94 | 2019-2023 | Zeposia |
| Ares Trading Sa | $660.00 | 2024 | Evobrutinib |
| Horizon Therapeutics Plc | $146.76 | 2021-2023 | Uplizna |
| Alexion Pharmaceuticals, INC. | $119.81 | 2019-2023 | Ultomiris, Soliris |
| Banner Life Sciences, LLC | $115.03 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $108.02 | 2019 | |
| Csl Behring | $79.94 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.